The quest for non-invasive delivery of bioactive macromolecules: A focus on heparins

Journal of Controlled Release

Volumn 113, Issue 2, 2006, Pages 91-101

  Motlekar, Nusrat A ^a   Youan, Bi Botti C ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Alternative routes; Bioactive macromolecule; Drug delivery; Heparin; Non invasive

Indexed keywords

BIOCHEMISTRY; DRUG PRODUCTS; MOLECULAR WEIGHT; NANOTECHNOLOGY; PATIENT TREATMENT; PH EFFECTS;

ALTERNATIVE ROUTES; BIOACTIVE MACROMOLECULE; DRUG DELIVERY; HEPARIN; NON-INVASIVE;

CONTROLLED DRUG DELIVERY;

ARDEPARIN; CARBOMER; CERTOPARIN; CHITOSAN DERIVATIVE; CHLOROCRESOL; DALTEPARIN; DEOXYCHOLATE SODIUM; DIAMINE; DRUG CARRIER; EDETIC ACID; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LABRASOL; LOW MOLECULAR WEIGHT HEPARIN; OCTANOIC ACID; OIL; PHOSPHATIDYLCHOLINE; POLYCARBOPHIL; RINGER SOLUTION; SAPONIN; SERINE PROTEINASE INHIBITOR; SODIUM LAURYLSARCOSINATE; SODIUM N [8 (2 HYDROXYBENZOYL)AMINO]CAPRYLATE; SODIUM N [8 (2 HYDROXYBENZOYL)AMINO]DECANOATE; SURFACTANT; TINZAPARIN; UNCLASSIFIED DRUG; WARFARIN;

APPLICATION SITE IRRITATION; ARTERY THROMBOSIS; CELL MEMBRANE PERMEABILITY; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG FORMULATION; DRUG MANUFACTURE; ELECTROPORATION; ENDOMETRITIS; FOOD AND DRUG ADMINISTRATION; GENOMICS; HEART ATRIUM FIBRILLATION; HUMAN; IONTOPHORESIS; LIPID SOLUBILITY; MACROMOLECULE; MICROEMULSION; NANOTECHNOLOGY; NEBULIZER; NONHUMAN; OVARIAN VEIN; PH MEASUREMENT; PRIORITY JOURNAL; PROTEOMICS; RESTENOSIS; REVIEW; SKIN PENETRATION; STOMACH PH; SUSTAINED DRUG RELEASE; THROMBOEMBOLISM; THROMBOPHLEBITIS; TIGHT JUNCTION; VAGINAL DELIVERY; VEIN THROMBOSIS;

ANIMALS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; HEPARIN; HUMANS; MACROMOLECULAR SUBSTANCES;

EID: 33745274728     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.04.008     Document Type: Review

References (147)

1. Bates S.M., and Weitz J.I. Emerging anticoagulant drugs. Arterioscler. Thromb. Vasc. Biol. 23 9 (2003) 1491-1500
2. Linkins L.A., and Weitz J.I. New anticoagulant therapy. Annu. Rev. Med. 56 (2005) 63-77
3. McLean J. The thromboplastic action of heparin. Am. J. Physiol. 41 (1916) 250-257
4. Messmore H.L., Wehrmacher W.H., Coyne E., and Fareed J. Heparin to pentasaccharide and beyond: the end is not in sight. Semin. Thromb. Hemost. 30 Suppl 1 (2004) 81-88
5. Lever R., and Page C.P. Novel drug development opportunities for heparin. Nat. Rev. Drug Discov. 1 2 (2002) 140-148
6. Caughey G.H. Building a better heparin. Am. J. Respir. Cell Mol. Biol. 28 2 (2003) 129-132
7. Ross B.P., and Toth I. Gastrointestinal absorption of heparin by lipidization or coadministration with penetration enhancers. Curr. Drug Deliv. 2 3 (2005) 277-287
8. Pineo G., Hull R., and Marder V. Oral delivery of heparin: SNAC and related formulations. Best Pract. Res. Clin. Haematol. 17 1 (2004) 153-160
9. Hiebert L.M. Oral heparins. Clin. Lab. 48 3-4 (2002) 111-116
10. Windsor E., and Freeman L. An investigation of routes of administration of heparin other than injection. Am. J. Med. 37 (1964) 408-416
11. Weitz J.I. New anticoagulants for treatment of venous thromboembolism. Circulation 110 9 Suppl 1 (2004) I19-I26
12. Verheugt F.W., Dieker H., and Aengevaeren W.R. Antithrombotic therapy during percutaneous coronary interventions. Ned. Tijdschr. Geneeskd. 149 17 (2005) 912-916
13. Medina R.P., and Foto D. The use of bivalirudin to prevent subacute thrombosis during drug-eluting stent implantation. J. Invasive Cardiol. 16 5 (2004) 236-239
14. Rha S.W., Kuchulakanti P.K., Pakala R., Cheneau E., Pinnow E., Gebreeyesus A., Aggrey G., Pichard A.D., Satler L.F., Kent K.M., Lindsay J., and Waksman R. Addition of heparin to contrast media is associated with increased bleeding and peripheral vascular complications during percutaneous coronary intervention with bivalirudin and drug-eluting stents. Cardiovasc. Radiat. Med. 5 2 (2004) 64-70
15. Roffi M., and Topol E.J. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. Eur. Heart. J. 25 3 (2004) 190-198
16. Wang H.J., Lin Z.X., Liu X.M., Sheng S.Y., and Wang J.Y. Heparin-loaded zein microsphere film and hemocompatibility. J. Control. Release 105 1-2 (2005) 120-131
17. Whelan D.M., van Beusekom H.M., and van der Giessen W.J. Mechanisms of drug loading and release kinetics. Semin. Interv. Cardiol. 3 3-4 (1998) 127-131
18. Hwang C.W., Wu D., and Edelman E.R. Physiological transport forces govern drug distribution for stent-based delivery. Circulation 104 5 (2001) 600-605
19. Thomas A.C., and Campbell J.H. Targeted delivery of heparin and LMWH using a fibrin antibody prevents restenosis. Atherosclerosis 176 1 (2004) 73-81
20. Park Y.J., Liang J.F., Song H., Li Y.T., Naik S., and Yang V.C. ATTEMPTS: a heparin/protamine-based triggered release system for the delivery of enzyme drugs without associated side-effects. Adv. Drug Deliv. Rev. 55 2 (2003) 251-265
21. Schafer A.I. Low-molecular-weight heparin-an opportunity for home treatment of venous thrombosis. N. Engl. J. Med. 334 11 (1996) 724-725
22. Goldshmidt O., Yeikilis R., Mawasi N., Paizi M., Gan N., Ilan N., Pappo O., Vlodavsky I., and Spira G. Heparanase expression during normal liver development and following partial hepatectomy. J. Pathol. 203 1 (2004) 594-602
23. Kim B.T., Kim W.S., Kim Y.S., Linhardt R.J., and Kim D.H. Purification and characterization of a novel heparinase from Bacteroides stercoris HJ-15. J. Biochem. (Tokyo) 128 2 (2000) 323-328
24. Ahn M.Y., Shin K.H., Kim D.H., Jung E.A., Toida T., Linhardt R.J., and Kim Y.S. Characterization of a Bacteroides species from human intestine that degrades glycosaminoglycans. Can. J. Microbiol. 44 5 (1998) 423-429
25. Jandik K.A., Kruep D., Cartier M., and Linhardt R.J. Accelerated stability studies of heparin. J. Pharm. Sci. 85 1 (1996) 45-51
26. Larsen A.K., Rice K.G., Linhardt R.J., Wogan G., and Langer R. Resistance of heparinase-derived heparin fragments to biotransformation. J. Biol. Chem. 264 3 (1989) 1570-1577
27. Bjornsson T.D., Schneider D.E., and Hecht A.R. Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. J. Pharmacol. Exp. Ther. 245 3 (1988) 804-808
28. Goldberg M., and Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat. Rev. Drug Discov. 2 4 (2003) 289-295
29. Hiebert L.M., Wice S.M., McDuffie N.M., and Jaques L.B. The heparin target organ-the endothelium. Studies in a rat model. Q. J. Med. 86 5 (1993) 341-348
30. Lovich M.A., and Edelman E.R. Tissue average binding and equilibrium distribution: an example with heparin in arterial tissues. Biophys. J. 70 3 (1996) 1553-1559
31. Senel S., Kremer M., Nagy K., and Squier C. Delivery of bioactive peptides and proteins across oral (buccal) mucosa. Curr. Pharm. Biotechnol. 2 2 (2001) 175-186
32. Litwins J., Vorzimer J.J., Sussman L.N., Applezweig N., and Etess A.D. Sublingual administration of heparin. Proc. Soc. Exp. Biol. Med. 77 2 (1951) 325-326
33. Fuller H.L. Sublingual heparin in hyperlipemia; a preliminary report. Angiology 9 5 (1958) 311-313
34. Korochkin I.M., Fuller, and Sublingual heparin in hyperlipemia; a preliminary report H.L. Angiology 9 5 (1958) 311-313
35. Kardiologiia 8 7 (1968) 50-53
36. Kalliomaki L. Sublingual administration of heparin. Duodecim 68 7-8 (1952) 655-658
37. Engelberg H. Buccal and sublingual administration of heparin potassium (clarin); studies of plasma triglyceride lipolysis and heparin levels. J. Am. Med. Assoc. 169 12 (1959) 1322-1325
38. McDevitt E., Huebner R.D., and Wright I.S. Ineffectiveness of heparin by sublingual administration. J. Am. Med. Assoc. 148 13 (1952) 1123-1124
39. Wright I.S. An evaluation of anticoagulant therapy. Am. J. Med. 14 6 (1953) 720-730
40. Lasker S.E. Low molecular weight heparin-like preparations with oral activity. Semin. Thromb. Hemost. 11 1 (1985) 37-39
41. Folkman J., Langer R., Linhardt R.J., Haudenschild C., and Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 221 4612 (1983) 719-725
42. Chander C.L., Colville-Nash P.R., Moore A.R., Howat D.W., Desa F.M., and Willoughby D.A. The effects of heparin and cortisone on an experimental model of pannus. Int. J. Tissue React. 11 3 (1989) 113-116
43. Schmitz T., Leitner V.M., and Bernkop-Schnurch A. Oral heparin delivery: design and in vivo evaluation of a stomach-targeted mucoadhesive delivery system. J. Pharm. Sci. 94 5 (2005) 966-973
44. Larsen A.K., Lund D.P., Langer R., and Folkman J. Oral heparin results in the appearance of heparin fragments in the plasma of rats. Proc. Natl. Acad. Sci. U. S. A. 83 9 (1986) 2964-2968
45. Windsor E., and Cronheim G.E. Gastrointestinal absorption of heparin and synthetic heparinoids. Naturwissenschaften 190 (1961) 263-264
46. Engel R.H., and Riggi S.J. Intestinal absorption of heparin: a study of the interactions of components of oil-in-water emulsions. J. Pharm. Sci. 58 11 (1969) 1372-1375
47. Vasdev S., Sampson C.A., Longerich L., Prabhakaran V.M., and Parai S. Oral heparin normalizes blood pressure and elevated cytosolic calcium in hypertensive rats. Artery 19 3 (1992) 124-146
48. Brayden D., Creed E., O'Connell A., Leipold H., Agarwal R., and Leone-Bay A. Heparin absorption across the intestine: effects of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate in rat in situ intestinal instillations and in Caco-2 monolayers. Pharm. Res. 14 12 (1997) 1772-1779
49. Leone-Bay A., Paton D.R., Variano B., Leipold H., Rivera T., Miura-Fraboni J., Baughman R.A., and Santiago N. Acylated non-alpha-amino acids as novel agents for the oral delivery of heparin sodium, USP. J. Control. Release 50 1-3 (1998) 41-49
50. Hiebert L.M., Wice S.M., and Jaques L.B. Antithrombotic activity of oral unfractionated heparin. J. Cardiovasc. Pharmacol. 28 1 (1996) 26-29
51. Li Y., Wang W.P., Wang H.Y., and Cho C.H. Intragastric administration of heparin enhances gastric ulcer healing through a nitric oxide-dependent mechanism in rats. Eur. J. Pharmacol. 399 2-3 (2000) 205-214
52. Costantini V., Deveglia R., Stabile A., and Nenci G.G. Absorption and antithrombotic activity of unfractioned heparin after intraduodenal administration in rats. Blood Coagul. Fibrinolysis 11 1 (2000) 7-13
53. Kast C.E., Guggi D., Langoth N., and Bernkop-Schnurch A. Development and in vivo evaluation of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil. Pharm. Res. 20 6 (2003) 931-936
54. Thanou M., Verhoef J.C., Nihot M.T., Verheijden J.H., and Junginger H.E. Enhancement of the intestinal absorption of low molecular weight heparin (LMWH) in rats and pigs using Carbopol 934P. Pharm. Res. 18 11 (2001) 1638-1641
55. Yang T., Arnold J.J., and Ahsan F. Tetradecylmaltoside (TDM) enhances in vitro and in vivo intestinal absorption of enoxaparin, a low molecular weight heparin. J. Drug Target. 13 1 (2005) 29-38
56. Motlekar N.A., Srivenugopal K.S., Wachtel M.S., and Youan B.B. Oral delivery of low-molecular-weight heparin using sodium caprate as absorption enhancer reaches therapeutic levels. J. Drug Target. 13 10 (2005) 573-583
57. Andriuoli G., Caramazza I., Galimberti G., Zoppetti G., Benedini F., Sala A., and Del Soldato P. Intraduodenal absorption in the rabbit of a novel heparin salt. Haemostasis 22 3 (1992) 113-116
58. Jiao Y., Ubrich N., Marchand-Arvier M., Vigneron C., Hoffman M., Lecompte T., and Maincent P. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 105 2 (2002) 230-235
59. Welt F.G., Woods T.C., and Edelman E.R. Oral heparin prevents neointimal hyperplasia after arterial injury: inhibitory potential depends on type of vascular injury. Circulation 104 25 (2001) 3121-3124
60. Ueno M., Nakasaki T., Horikoshi I., and Sakuragawa N. Oral administration of liposomally-entrapped heparin to beagle dogs. Chem. Pharm. Bull. (Tokyo) 30 6 (1982) 2245-2247
61. Dryjski M., Schneider D.E., Mojaverian P., Kuo B.S., and Bjornsson T.D. Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations. Br. J. Clin. Pharmacol. 28 2 (1989) 188-192
62. Horwitz O., Johnson W.T., Sayen J.J., Roberts B., and Whereat A.F. Heparin for oral use: preliminary studies. Trans. Am. Clin. Climatol. Assoc. 104 (1992) 94-102 (discussion 102-103)
63. Imiela J., Nosarzewski J., and Gorski A. Oral heparin in the treatment of rheumatoid arthritis. Arch. Immunol. Ther. Exp. (Warsz) 43 5-6 (1995) 313-315
64. Cui H.F., and Jiang X.L. Treatment of corticosteroid-resistant ulcerative colitis with oral low molecular weight heparin. World J. Gastroenterol. 5 5 (1999) 448-450
65. Hiebert L.M., Wice S.M., and Ping T. Increased plasma anti-Xa activity and recovery of heparin from urine suggest absorption of orally administered unfractionated heparin in human subjects. J. Lab. Clin. Med. 145 3 (2005) 151-155
66. Berkowitz S.D., Marder V.J., Kosutic G., and Baughman R.A. Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty. J. Thromb. Haemost. 1 9 (2003) 1914-1919
67. Kim S.K., Vaishali B., Lee E., Lee S., Lee Y.K., Kumar T.S., Moon H.T., and Byun Y. Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation. Thromb. Res. 117 4 (2005) 419-427
68. Lee Y., Nam J.H., Shin H.C., and Byun Y. Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. Circulation 104 25 (2001) 3116-3120
69. Park K., Kim K., Kwon I.C., Kim S.K., Lee S., Lee D.Y., and Byun Y. Preparation and characterization of self-assembled nanoparticles of heparin-deoxycholic acid conjugates. Langmuir 20 26 (2004) 11726-11731
70. Hayes P.Y., Ross B.P., Thomas B.G., and Toth I. Polycationic lipophilic-core dendrons as penetration enhancers for the oral administration of low molecular weight heparin. Bioorg. Med. Chem. 14 1 (2006) 143-152
71. Rama Prasad Y.V., Minamimoto T., Yoshikawa Y., Shibata N., Mori S., Matsuura A., and Takada K. In situ intestinal absorption studies on low molecular weight heparin in rats using labrasol as absorption enhancer. Int. J. Pharm. 271 1-2 (2004) 225-232
72. Engel R.H., and Riggi S.J. Effect of sulfated and sulfonated surfactants on the intestinal absorption of heparin. Proc. Soc. Exp. Biol. Med. 130 3 (1969) 879-884
73. Cho S.Y., Sim J.S., Kang S.S., Jeong C.S., Linhardt R.J., and Kim Y.S. Enhancement of heparin and heparin disaccharide absorption by the Phytolacca americana saponins. Arch. Pharm. Res. 26 12 (2003) 1102-1108
74. Thanou M., Nihot M.T., Jansen M., Verhoef J.C., and Junginger H.E. Mono-N-carboxymethyl chitosan (MCC), a polyampholytic chitosan derivative, enhances the intestinal absorption of low molecular weight heparin across intestinal epithelia in vitro and in vivo. J. Pharm. Sci. 90 1 (2001) 38-46
75. Bernkop-Schnurch A., Hornof M., and Zoidl T. Thiolated polymers-thiomers: synthesis and in vitro evaluation of chitosan-2-iminothiolane conjugates. Int. J. Pharm. 260 2 (2003) 229-237
76. N. Motlekar, A. Fasano, M. Wachtel, B.B. Youan, Zonula occludens toxin synthetic peptide derivative AT1002 enhances in vitro and in vivo intestinal absorption of low-molecular-weight-heparin. Journal of Drug Targeting (in press).
77. Dal Pozzo A., Acquasaliente M., Geron M.R., and Andriuoli G. New heparin complexes active by intestinal absorption: I. Multiple ion pairs with basic organic compounds. Thromb. Res. 56 1 (1989) 119-124
78. Gonze M.D., Manord J.D., Leone-Bay A., Baughman R.A., Garrard C.L., Sternbergh III W.C., and Money S.R. Orally administered heparin for preventing deep venous thrombosis. Am .J. Surg. 176 2 (1998) 176-178
79. Rivera T.M., Leone-Bay A., Paton D.R., Leipold H.R., and Baughman R.A. Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate: pharmacological considerations. Pharm. Res. 14 12 (1997) 1830-1834
80. Andersson M., and Lofroth J.E. Small particles of a heparin/chitosan complex prepared from a pharmaceutically acceptable microemulsion. Int. J. Pharm. 257 1-2 (2003) 305-309
81. Dufresne M.H., and Leroux J.C. Study of the micellization behavior of different order amino block copolymers with heparin. Pharm. Res. 21 1 (2004) 160-169
82. Tenjarla S. Microemulsions: an overview and pharmaceutical applications. Crit. Rev. Ther. Drug Carrier Syst. 16 5 (1999) 461-521
83. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug. Discov. 2 5 (2003) 347-360
84. Gregoriadis G. Tailoring liposome structure. Nature 283 5750 (1980) 814-815
85. Doutremepuich C., Toulemonde F., and Lormeau J.C. Oral administration of low molecular weight heparin fractions in rabbits. Semin. Thromb. Hemost. 11 3 (1985) 323-325
86. G. Andriuoli, M. Bossi, I. Caramazza, G. Zoppetti, Heparin by alternative routes of administration, (1990).
87. Chandy T., Rao G.H., Wilson R.F., and Das G.S. Delivery of LMW heparin via surface coated chitosan/peg-alginate microspheres prevents thrombosis. Drug Deliv. 9 2 (2002) 87-96
88. Sue T.K., Jaques L.B., and Yuen E. Effects of acidity, cations and alcoholic fractionation on absorption of heparin from gastrointestinal tract. Can. J. Physiol. Pharmacol. 54 4 (1976) 613-617
89. Mathiowitz E., Jacob J.S., Jong Y.S., Carino G.P., Chickering D.E., Chaturvedi P., Santos C.A., Vijayaraghavan K., Montgomery S., Bassett M., and Morrell C. Biologically erodible microspheres as potential oral drug delivery systems. Nature 386 6623 (1997) 410-414
90. Florence A.T. The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm. Res. 14 3 (1997) 259-266
91. Prego C., Garcia M., Torres D., and Alonso M.J. Transmucosal macromolecular drug delivery. J. Control. Release 101 1-3 (2005) 151-162
92. Senior N. Rectal administration of drugs. Adv. Pharm. Sci. 4 (1974) 363-435
93. Nissan A., Ziv E., Kidron M., Bar-On H., Friedman G., Hyam E., and Eldor A. Intestinal absorption of low molecular weight heparin in animals and human subjects. Haemostasis 30 5 (2000) 225-232
94. Ziv E., Eldor A., Kleinman Y., Bar-On H., and Kidron M. Bile salts facilitate the absorption of heparin from the intestine. Biochem. Pharmacol. 32 5 (1983) 773-776
95. Stanzani L., Mascellani G., Corbelli G.P., and Bianchini P. Rectal absorption of some glycosaminoglycan sulphates and heparin in rats. J. Pharm. Pharmacol. 33 12 (1981) 783-786
96. Miyake M., Nishihata T., Wada N., Takeshima E., and Kamada A. Rectal absorption of lysozyme and heparin in rabbits in the presence of non-surfactant adjuvants. Chem. Pharm. Bull. (Tokyo) 32 5 (1984) 2020-2025
97. Robinson M. Optimizing therapy for inflammatory bowel disease. Am. J. Gastroenterol. 92 12 Suppl (1997) 12S-17S
98. Cyrkowicz A., Fiala J., Kacalski J., Jackowski P., Bielaszka K., and Smida A. Prevention of deep vein thrombosis (DVT) with the low molecular weight heparin (LMWH) and epidural/spinal anesthesia. The efficacy viewpoint. Ginekol. Pol. 69 11 (1998) 795-799
99. Magee K.P., Blanco J.D., and Graham J.M. Massive septic pelvic thrombophlebitis. Obstet. Gynecol. 82 4 Pt 2 Suppl (1993) 662-664
100. Witlin A.G., and Sibai B.M. Postpartum ovarian vein thrombosis after vaginal delivery: a report of 11 cases. Obstet. Gynecol. 85 5 Pt 1 (1995) 775-780
101. Suman J.D. Nasal drug delivery. Expert Opin. Biol. Ther. 3 3 (2003) 519-523
102. Mustafa F., Yang T., Khan M.A., and Ahsan F. Chain length-dependent effects of alkylmaltosides on nasal absorption of enoxaparin. J. Pharm. Sci. 93 3 (2004) 675-683
103. Pillion D.J., Ahsan F., Arnold J.J., Balusubramanian B.M., Piraner O., and Meezan E. Synthetic long-chain alkyl maltosides and alkyl sucrose esters as enhancers of nasal insulin absorption. J. Pharm. Sci. 91 6 (2002) 1456-1462
104. Zeng D., Prosperini G., Russo C., Spicuzza L., Cacciola R.R., Di Maria G.U., and Polosa R. Heparin attenuates symptoms and mast cell degranulation induced by AMP nasal provocation. J. Allergy Clin. Immunol. 114 2 (2004) 316-320
105. Vancheri C., Mastruzzo C., Armato F., Tomaselli V., Magri S., Pistorio M.P., LaMicela M., D'Amico L., and Crimi N. Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis. J. Allergy Clin. Immunol. 108 5 (2001) 703-708
106. Uryvaev I.V., Iudel'son I.B., and Sergeev V.V. Changes in hemostasis and vagal tonus in healthy individuals and patients with facial neuropathy by micro-dose heparin stimulation of nasal receptors. Vestn. Ross. Akad. Med. Nauk. 8 (1997) 22-23
107. Arnold J., Ahsan F., Meezan E., and Pillion D.J. Nasal administration of low molecular weight heparin. J Pharm Sci 91 7 (2002) 1707-1714
108. Vidgren M.T., and Kublik H. Nasal delivery systems and their effect on deposition and absorption. Adv. Drug Deliv. Rev. 29 1-2 (1998) 157-177
109. Edwards D.A., and Dunbar C. Bioengineering of therapeutic aerosols. Annu. Rev. Biomed. Eng. 4 (2002) 93-107
110. Jaques L.B., Mahadoo J., and Kavanagh L.W. Intrapulmonary heparin. A new procedure for anticoagulant therapy. Lancet 2 7996 (1976) 1157-1161
111. Berry L.R., Klement P., Andrew M., and Chan A.K. Effect of covalent serpin-heparinoid complexes on plasma thrombin generation on fetal distal lung epithelium. Am. J. Respir. Cell. Mol. Biol. 28 2 (2003) 150-158
112. Yang T., Mustafa F., Bai S., and Ahsan F. Pulmonary delivery of low molecular weight heparins. Pharm. Res. 21 11 (2004) 2009-2016
113. Seeds E.A., Horne A.P., Tyrrell D.J., and Page C.P. The effect of inhaled heparin and related glycosaminoglycans on allergen-induced eosinophil infiltration in guinea-pigs. Pulm. Pharmacol. 8 2-3 (1995) 97-105
114. Gunther A., Lubke N., Ermert M., Schermuly R.T., Weissmann N., Breithecker A., Markart P., Ruppert C., Quanz K., Ermert L., Grimminger F., and Seeger W. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am. J. Respir. Crit. Care Med. 168 11 (2003) 1358-1365
115. Qi Y., Zhao G., Liu D., Shriver Z., Sundaram M., Sengupta S., Venkataraman G., Langer R., and Sasisekharan R. Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route. Proc. Natl. Acad. Sci. U. S. A. 101 26 (2004) 9867-9872
116. Ahmed T., Abraham W.M., and D'Brot J. Effects of inhaled heparin on immunologic and nonimmunologic bronchoconstrictor responses in sheep. Am. Rev. Respir. Dis. 145 3 (1992) 566-570
117. Patton J. Breathing life into protein drugs. Nat. Biotechnol. 16 2 (1998) 141-143
118. Wang Q.L., Shang X.Y., Zhang S.L., Ji J.B., Cheng Y.N., Meng Y.J., and Zhu Y.J. Effects of inhaled low molecular weight heparin on airway allergic inflammation in aerosol-ovalbumin-sensitized guinea pigs. Jpn. J. Pharmacol. 82 4 (2000) 326-330
119. Bowler S.D., Smith S.M., and Lavercombe P.S. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am. Rev. Respir. Dis. 147 1 (1993) 160-163
120. Bendstrup K.E., and Jensen J.I. Inhaled heparin is effective in exacerbations of asthma. Respir. Med. 94 2 (2000) 174-175
121. Sznitowska M., and Janicki S. Percutaneous absorption of heparin: a critical review of experimental results. Pol .Merkuriusz. Lek. 7 43 (2000) 58-63
122. Zesch A., and Schaefer H. Penetration, permeation and resorption of heparin. In vivo studies on human skin. Arzneimittelforschung 26 7 (1976) 1365-1368
123. Fu K., Izquierdo R., Vandevender D., Warpeha R.L., Wolf H., and Fareed J. Topical application of low molecular weight heparin in a rabbit traumatic anastomosis model. Thromb. Res. 86 5 (1997) 355-361
124. Katzenschlager R., Ugurluoglu A., and Hirsch M. Liposomal heparin-spraygel in comparison with subcutaneous low molecular weight heparin in patients with superficial venous thrombosis. A randomized, controlled, open multicentre study. J. Kardiol. 10 9 (2003) 375-378
125. Betz G., Nowbakht P., Imboden R., and Imanidis G. Heparin penetration into and permeation through human skin from aqueous and liposomal formulations in vitro. Int. J. Pharm 228 1-2 (2001) 147-159
126. Mitragotri S., and Kost J. Transdermal delivery of heparin and low-molecular weight heparin using low-frequency ultrasound. Pharm. Res. 18 8 (2001) 1151-1156
127. Le L., Kost J., and Mitragotri S. Combined effect of low-frequency ultrasound and iontophoresis: applications for transdermal heparin delivery. Pharm. Res. 17 9 (2000) 1151-1154
128. Prausnitz M.R., Edelman E.R., Gimm J.A., Langer R., and Weaver J.C. Transdermal delivery of heparin by skin electroporation. Biotechnology (N Y) 13 11 (1995) 1205-1209
129. Vanbever R., Prausnitz M.R., and Preat V. Macromolecules as novel transdermal transport enhancers for skin electroporation. Pharm. Res. 14 5 (1997) 638-644
130. Weaver J.C., Vanbever R., Vaughan T.E., and Prausnitz M.R. Heparin alters transdermal transport associated with electroporation. Biochem. Biophys. Res. Commun. 234 3 (1997) 637-640
131. Mitchel J.F., Azrin M.A., Fram D.B., Bow L.M., and McKay R.G. Localized delivery of heparin to angioplasty sites with iontophoresis. Catheter. Cardiovasc. Diagn. 41 3 (1997) 315-323
132. Hollingsworth S.J., Hoque K., Linnard D., Corry D.G., and Barker S.G. Delivery of low molecular weight heparin for prophylaxis against deep vein thrombosis using a novel, needle-less injection device (J-Tip). Ann. R. Coll. Surg. Engl. 82 6 (2000) 428-431
133. McAllister D.V., Wang P.M., Davis S.P., Park J.H., Canatella P.J., Allen M.G., and Prausnitz M.R. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc. Natl. Acad. Sci. U. S. A. 100 24 (2003) 13755-13760
134. Mitragotri S. Healing sound: the use of ultrasound in drug delivery and other therapeutic applications. Nat. Rev. Drug Discov. 4 3 (2005) 255-260
135. Backhed F., Ley R.E., Sonnenburg J.L., Peterson D.A., and Gordon J.I. Host-bacterial mutualism in the human intestine. Science 307 5717 (2005) 1915-1920
136. Cossart P., and Sansonetti P.J. Bacterial invasion: the paradigms of enteroinvasive pathogens. Science 304 5668 (2004) 242-248
137. Mullen L.M., Nair S.P., Ward J.M., Rycroft A.N., and Henderson B. Phage display in the study of infectious diseases. Trends Microbiol. 14 3 (2006) 141-147
138. Peppas N.A., and Huang Y. Nanoscale technology of mucoadhesive interactions. Adv. Drug Deliv. Rev. 56 11 (2004) 1675-1687
139. Sulchek T.A., Friddle R.W., Langry K., Lau E.Y., Albrecht H., Ratto T.V., DeNardo S.J., Colvin M.E., and Noy A. Dynamic force spectroscopy of parallel individual Mucin1-antibody bonds. Proc. Natl. Acad. Sci. U. S. A. 102 46 (2005) 16638-16643
140. Farokhzad O.C., Khademhosseini A., Jon S., Hermmann A., Cheng J., Chin C., Kiselyuk A., Teply B., Eng G., and Langer R. Microfluidic system for studying the interaction of nanoparticles and microparticles with cells. Anal. Chem. 77 17 (2005) 5453-5459
141. Saad O.M., and Leary J.A. Delineating mechanisms of dissociation for isomeric heparin disaccharides using isotope labeling and ion trap tandem mass spectrometry. J. Am. Soc. Mass. Spectrom. 15 9 (2004) 1274-1286
142. Veber D.F., Johnson S.R., Cheng H.Y., Smith B.R., Ward K.W., and Kopple K.D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45 12 (2002) 2615-2623
143. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev. 46 1-3 (2001) 3-26
144. Karande P., Jain A., Ergun K., Kispersky V., and Mitragotri S. Design principles of chemical penetration enhancers for transdermal drug delivery. Proc. Natl. Acad. Sci. U. S. A. 102 13 (2005) 4688-4693
145. Schanker L.S., and Burton J.A. Absorption of heparin and cyanocobalamin from the rat lung. Proc. Soc. Exp. Biol. Med. 152 3 (1976) 377-380
146. Ahmed T., Garrigo J., and Danta I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N. Engl. J. Med. 329 2 (1993) 90-95
147. Bendstrup K.E., Gram J., and Jensen J.I. Effect of inhaled heparin on lung function and coagulation in healthy volunteers. Eur. Respir. J. 19 4 (2002) 606-610